Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 3/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24034891 | 1.00 | FFAR2 (0.36) | FFAR2PIK3CDPIK3CBPIK3CGPIK3CA | |
| SCHEMBL24034901 | 0.90 | SMN1; SMN2 (0.35) | HCRTR1HCRTR2CYP3A4PDE3BPDE3A | |
| SCHEMBL26096525 | 0.90 | SMN1; SMN2 (0.35) | HCRTR1HCRTR2CYP3A4PDE3BPDE3A | |
| SCHEMBL24034712 | 0.90 | SMN1; SMN2 (0.35) | HCRTR1HCRTR2CYP3A4PDE3BPDE3A | |
| SCHEMBL24034794 | 0.88 | L3MBTL1 (0.45) | PIK3CDPIK3CBPIK3CAL3MBTL1 | |
| SCHEMBL24034786 | 0.82 | CACNA2D1 (0.32) | — | |
| SCHEMBL24034787 | 0.82 | DRD2 (0.34) | — | |
| SCHEMBL30111766 | 0.82 | DRD2 (0.34) | — | |
| SCHEMBL28906140 | 0.82 | — | — | |
| SCHEMBL24034844 | 0.81 | FFAR2 (0.34) | FFAR2PIK3CDPIK3CBPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | claimed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | claimed |
| EP-4149933-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-22 | — | — | EP | claimed |
| CN-115461337-A | Novel triazolyl derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4149933-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-22 | — | — | EP | disclosed |
| CN-115461337-A | Novel triazolyl derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | FFAR2 1469/4885PIK3CD 2128/4885PIK3CB 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.